Clinical trials: Lung Tumors
Esophageal Cancer, Lung Cancer
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens.
- Conditions
- Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer
- Trial name
- NCT00291473
- Testing
- CHP-HER2, CHP-NY-ESO-1
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00003583
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
ALK TKIs, particularly second- and third-generation ALK TKIs, have significantly improved progression-free survival (PFS) in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07671560
- Testing
- Combined group of ensatinib and arotinib
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Qiming Wang
PROMs
Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen
A multicenter, national pharmacological observational study that has as its overall goal to implement a set of validated and agreed upon European-wide questionnaires (PROMs - patient's reported outcomes) to assess patients'…
- Trial name
- PROMOTING (NCT07061379)
- Testing
- Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity, Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity
- Where
- Italy
- Volunteers
- 144 people
- Sponsor
- IRCCS San Raffaele
Lung Cancer
Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage…
- Trial name
- NCT00003062
- Testing
- temozolomide
- Where
- 5 sites in Italy, Netherlands and 3 more
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Weight Loss, Cachexia
Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer (LEKS)
Weight loss and loss of lean body mass are common and associated with adverse outcomes such as loss of strength, reduced immune- and pulmonary function and increased disability in advanced cancer.
- Trial name
- LEKS (NCT01865903)
- Where
- Norway
- Volunteers
- 17 people
- Sponsor
- Oslo University Hospital
Stage IIIA Non-small Cell Lung Cancer
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients
This is a single arm, single center phase II study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) patients treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection.
- Trial name
- NCT03053856
- Testing
- Pembrolizumab, Curative resection, Neoadjuvant concurrent chemoradiotherapy
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Samsung Medical Center
Lung Cancer
Postoperative Pain After Single Port, Two Ports and Three Ports VATS Lobectomy
This single-center, prospective, randomized controlled trial was designed to assess and compare the postoperative pain after VATS lobectomy performed though one, two and three incisions.
- Trial name
- NCT03228056
- Testing
- pain intensity measured in VAS scale
- Where
- 2 sites in Poland
- Volunteers
- 90 people
- Sponsor
- Pulmonary Hospital Zakopane
Rheumatoid Arthritis (RA), Lung Neoplasms
The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer
Patients with rheumatoid arthritis (RA) have an increased risk of lung cancer, potentially influenced by targeted therapies such as JAK inhibitors and biologics.
- Trial name
- RAPTOR (NCT07913256)
- Volunteers
- 136 people
- Sponsor
- University Hospital, Limoges
Lung Cancer
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
This study is a prospective, single-arm, single-center Phase II trial, aiming to investigate efficacy and safety of neoadjuvant chemotherapy sequentially combined with sintilimab in resectable EGFR-mutant stage II-IIIB…
- Trial name
- Peri-E (NCT06688656)
- Testing
- Pemetrexed 500 mg/m2, carboplatin, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Radiation Pneumonitis
Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients
This project will test the effect of nicorandil to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer.
- Trial name
- NCT02809456
- Testing
- Nicorandil
- Volunteers
- 50 people
- Sponsor
- Taipei Medical University WanFang Hospital
Non Small Cell Lung Cancer Metastatic
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
This study includes the additional use of radiation therapy in combination immunotherapy in order to determine whether the radiation may improve the response of non-small cell lung cancer to immunotherapy and to monitor any side…
- Trial name
- NCT03035890
- Testing
- Radiation, Immuno-Therapeutic Agent
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- West Virginia University
Carcinoma, Non-Small-Cell Lung
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
The main aim of this study is to evaluate the safety and tolerability of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s)…
- Trial name
- NCT02044380
- Testing
- Afatinib
- Where
- 5 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Cancer (Advanced Stage)
Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors
This single-site, randomized pilot study will evaluate whether intermittent fasting is feasible and safe for patients with advanced solid tumors who are starting immune checkpoint inhibitor (ICI) therapy at the WVU Cancer…
- Trial name
- NCT07645742
- Testing
- Alternate-Day Fasting (ADF), Time-Restricted Eating (TRE)
- Volunteers
- 90 people
- Sponsor
- West Virginia University
Non Small Cell Lung Cancer
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of…
- Trial name
- NCT01048983
- Testing
- Armodafinil, Bupropion, Minocycline
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Colon Cancer
Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
The study will look at conducting a medium-intense walking program called Walk With Ease with cancer patients age 60 and above who are starting chemotherapy treatment.
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer
- Trial name
- WWE (NCT01789983)
- Testing
- Walk With Ease Program, Collect Blood, GA and Other Survey Tools
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer, Sarcoidosis
Comparison of Three Different Puncture Techniques in EBUS-TBNA
The purpose of this study was to compare the accuracy and sensitivity of slow-pull capillary technique, traditional suction aspiration and non negative pressure puncture in the diagnosis of mediastinal and/or hilar lymph node…
- Conditions
- Lung Cancer, Sarcoidosis, Tuberculosis
- Trial name
- NCT05628454
- Testing
- Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling, Endobronchial ultrasound-guided transbronchial needle aspiration, Endobronchial ultrasound-guided transbronchial needle capillary sampling
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Beijing Friendship Hospital
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Lung Cancer, Squamous Cell Carcinoma of the Lung
Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma
Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves the use of chemotherapy as the therapeutic mainstay.
- Conditions
- Lung Cancer, Squamous Cell Carcinoma of the Lung, Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung
- Trial name
- NCT01947062
- Testing
- Intravenous Cisplatin & etoposide, Intravenous Cisplatin & etoposide along with oral cyclophosphamide
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Swami Rama Cancer Hospital and Research Institute
Carcinoma, Non-Small-Cell Lung
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
This is an international, multi-center, prospective, randomized, open-label Phase 3 clinical trial of the cancer stemness inhibitor napabucasin administered with weekly paclitaxel versus weekly paclitaxel alone in patients with…
- Trial name
- CanStem43L (NCT02826161)
- Testing
- Napabucasin, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.